Added to YB: 2026-04-09
Pitch date: 2026-04-08
BCHMY [neutral]
Bachem Holding AG
Author Info
No bio for this author
Company Info
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Market Cap
CHF 5.0B
Pitch Price
N/A
Price Target
N/A
Dividend
1.35%
EV/EBITDA
23.89
P/E
33.65
EV/Sales
7.24
Sector
Life Sciences Tools and Services
Category
growth
Bachem: Mispriced as GLP-1, Positioned for Structural Peptide Growth
BCHMY (overview): Mispriced as GLP-1 play, actually peptide CDMO w/ CMC pipeline converting to recurring commercial rev. GLP-1 validated peptides, accelerating broader clinical activity. CMC Development +29.7% YoY to CHF304M vs Commercial API +5% to CHF343.4M shows pipeline shift. Bachem = manufacturing bottleneck for structural peptide expansion across pharma/biotech.
Read full article (1 min)